Drug intelligence / Profile preview

HIP1802

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HIP1802 is a small molecule drug developed by Hanmi Pharmaceutical. It has been evaluated in at least one completed Phase 1 clinical trial comparing its safety, pharmacokinetics, and pharmacodynamics to HGP1705 in healthy volunteers. The specific mechanism of action, molecular target(s), and therapeutic indications for HIP1802 have not been publicly disclosed as of the latest available data. Its global highest R&D status is listed as "Pending," indicating that it has not advanced beyond early clinical development or received regulatory approval[1][2][10].

Beyond the preview

Go deeper on HIP1802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIP1802.

Explore the full profile